Nvidia-Backed Iambic Therapeutics Files for Nasdaq IPO

Nvidia-backed Iambic Therapeutics filed Monday for a U.S. initial public offering, planning to list on Nasdaq under the ticker IAM and giving public investors a new way to bet on the intersection of artificial intelligence and drug discovery.

The San Diego biotech did not disclose the number of shares or a proposed price range in its filing. Renaissance Capital reported that the offering could raise as much as $100 million. Iambic plans to direct proceeds primarily at advancing three cancer-drug programs through development.

Founded in 2019, Iambic combines artificial intelligence with automated chemistry and biology to identify and develop small-molecule medicines. The company has raised roughly $461.8 million to date from investors including Nvidia (NASDAQ: NVDA), Qatar Investment Authority, Coatue Management, Catalio and Nexus Ventures.

The company's lead asset is IAM1363, an experimental oral HER2 inhibitor currently being evaluated in a Phase 1/1b study for solid tumors. Two additional candidates, IAM217 and IAM-C1, remain in preclinical development.

That pipeline profile makes the offering a higher-risk test of the AI-drug-discovery thesis. Iambic sits early in clinical development, which means its eventual valuation will depend heavily on whether its AI platform can translate promising computational drug design into successful human trials.

The company does carry significant pharmaceutical validation. Iambic has collaborations with AbbVie, Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals and Bayer, giving it relationships with established drugmakers as it builds out its platform.

The central question for investors is not simply whether Iambic completes its IPO, but what valuation public markets will assign to an AI-driven biotech whose lead program remains in early-stage trials. Strong Phase 1 data for IAM1363 could strengthen the investment case considerably, while disappointing safety or efficacy results would expose how much of Iambic's valuation rests on AI-driven expectations rather than proven drug-development economics.

Ahead of the pricing, investors will be watching the eventual IPO price range, the company's cash runway, clinical timelines for IAM1363 and any milestone payments triggered by its pharmaceutical partnerships.